Marizomib for central nervous system-multiple myeloma

被引：61

作者：

Badros, Ashraf ^{[1
]}

Singh, Zeba ^{[1
]}

Dhakal, Binod ^{[2
]}

Kwok, Young ^{[1
]}

MacLaren, Ann ^{[3
]}

Richardson, Paul ^{[4
]}

Trikha, Mohit ^{[3
]}

Hari, Parameswaran ^{[2
]}

机构：

[1] Univ Maryland, Med Ctr, M&S Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[2] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA

[3] Triphase Accelerator, San Diego, CA USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2017年 / 177卷 / 02期

关键词：

multiple myeloma; central nervous system relapse; clinical studies; marizomib; INVOLVEMENT;

D O I：

10.1111/bjh.14498

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Marizomib, a natural marine product, is an irreversible proteasome inhibitor currently under investigation in relapsed-refractory multiple myeloma (RRMM) and malignant glioma. Central nervous system-multiple myeloma (CNS-MM) is a rare manifestation of extra-medullary disease with few therapeutic options, highlighting the unmet clinical need in these patients. Marizomib demonstrated encouraging activity in RRMM and has emerging clinical activity in glioma, making it a potential CNS-MM therapeutic intervention. Herein, we present two patients with RRMM and CNS involvement who benefited from marizomib-based therapy. Thesecases provide the first proof of principle for further exploring marizomib in CNS-MM patients.

引用

页码：221 / 225

页数：5

共 10 条

[1] Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma
Abdallah, Al-ola
Atrash, Shebli
Shahid, Zainab
Jameel, Muzaffar
Grazziutti, Monica
Apewokin, Senu
Kumar, Naveen S.
Restrepo, Alejandro
Waheed, Sarah
Van Rhee, Frits
Heuck, Christoph J.
Johann, Donald, Jr.
Barlogie, Bart
Usmani, Saad Z.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (03) : 211 - 214
[2] Bota D. A., 2016, CANC RES S, V76
[3] Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier
Di, Kaijun
Lloyd, G. Kenneth
Abraham, Vivek
MacLaren, Ann
Burrows, Francis J.
Desjardins, Annick
Trikha, Mohit
Bota, Daniela A.
[J]. NEURO-ONCOLOGY, 2016, 18 (06) : 840 - 848
[4] Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations
Fassas, ABT
Muwalla, F
Berryman, T
Benramdane, R
Joseph, L
Anaissie, E
Sethi, R
Desikan, R
Siegel, D
Badros, A
Toor, A
Zangari, M
Morris, C
Angtuaco, E
Mathew, S
Wilson, C
Hough, A
Harik, S
Barlogie, B
Tricot, G
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) : 103 - 108
[5] Emergence of central nervous system myeloma in the era of novel agents
Gangatharan, Shane A.
Carney, Dennis A.
Prince, H. Miles
Wolf, Max M.
Januszewicz, E. Henry
Ritchie, David S.
Harrison, Simon J.
[J]. HEMATOLOGICAL ONCOLOGY, 2012, 30 (04) : 170 - 174
[6] Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
Jurczyszyn, Artur
Grzasko, Norbert
Gozzetti, Alessandro
Czepiel, Jacek
Cerase, Alfonso
Hungria, Vania
Crusoe, Edvan
Miranda Silva Dias, Ana Luiza
Vij, Ravi
Fiala, Mark A.
Caers, Jo
Rasche, Leo
Nooka, Ajay K.
Lonial, Sagar
Vesole, David H.
Philip, Sandhya
Gangatharan, Shane
Druzd-Sitek, Agnieszka
Walewski, Jan
Corso, Alessandro
Cocito, Federica
Vekemans, Marie-Christine M.
Atilla, Erden
Beksac, Meral
Leleu, Xavier
Davila, Julio
Badros, Ashraf
Aneja, Ekta
Abildgaard, Niels
Kastritis, Efstathios
Fantl, Dorotea
Schutz, Natalia
Pika, Tomas
Butrym, Aleksandra
Olszewska-Szopa, Magdalena
Usnarska-Zubkiewicz, Lidia
Usmani, Saad Z.
Nahi, Hareth
Chim, Chor S.
Shustik, Chaim
Madry, Krzysztof
Lentzsch, Suzanne
Swiderska, Alina
Helbig, Grzegorz
Guzicka-Kazimierczak, Renata
Lendvai, Nikoletta
Waage, Anders
Andersen, Kristian T.
Murakami, Hirokazu
Zweegman, Sonja
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (06) : 575 - 580
[7] Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience
Katodritou, Eirini
Terpos, Evangelos
Kastritis, Efstathios
Delimpasis, Sossana
Symeonidis, Argiris S.
Repousis, Panagiotis
Kyrtsonis, Marie-Christine
Vadikolia, Chrysa
Michalis, Eurydiki
Polychronidou, Genovefa
Michael, Michael
Papadaki, Sofia
Papathanasiou, Maria
Kokoviadou, Kyriaki
Kioumi, Anna
Vlachaki, Eythimia
Hadjiaggelidou, Christina
Kouraklis, Alexandra
Patsias, Ioannis
Gavriatopoulou, Maria
Kotsopoulou, Maria
Verrou, Evgenia
Gastari, Vasiliki
Christoulas, Dimitrios
Giannopoulou, Evlambia
Pouli, Anastasia
Konstantinidou, Pavlina
Anagnostopoulos, Achilles
Dimopoulos, Meletios-Athanasios
[J]. ANNALS OF HEMATOLOGY, 2015, 94 (12) : 2033 - 2042
[8] Intracranial involvement by multiple myeloma
Lasocki, A.
Gangatharan, S.
Gaillard, F.
Harrison, S. J.
[J]. CLINICAL RADIOLOGY, 2015, 70 (08) : 890 - 897
[9] Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Lonial, Sagar
Weiss, Brendan M.
Usmani, Saad Z.
Singhal, Seema
Chari, Ajai
Bahlis, Nizar J.
Belch, Andrew
Krishnan, Amrita
Vescio, Robert A.
Victoria Mateos, Maria
Mazumder, Amitabha
Orlowski, Robert Z.
Sutherland, Heather J.
Blade, Joan
Scott, Emma C.
Oriol, Albert
Berdeja, Jesus
Gharibo, Mecide
Stevens, Don A.
LeBlanc, Richard
Sebag, Michael
Callander, Natalie
Jakubowiak, Andrzej
White, Darrell
de la Rubia, Javier
Richardson, Paul G.
Lisby, Steen
Feng, Huaibao
Uhlar, Clarissa M.
Khan, Imran
Ahmadi, Tahamtan
Voorhees, Peter M.
[J]. LANCET, 2016, 387 (10027) : 1551 - 1560
[10] Richardson PG, 2016, BLOOD, V127, P2693, DOI [10.1182/blood-2015-12686378, 10.1182/blood-2015-12-686378]

← 1 →